Skip to main navigation Skip to search Skip to main content

In Vitro Evaluation of Novel Nitazoxanide Derivatives against Mycobacterium tuberculosis

  • Joshua Odingo
  • , Mai A. Bailey
  • , Megan Files
  • , Julie V. Early
  • , Torey Alling
  • , Devon Dennison
  • , Julie Bowman
  • , Suryakanta Dalai
  • , Naresh Kumar
  • , Jeffrey Cramer
  • , Thierry Masquelin
  • , Philip A. Hipskind
  • , Tanya Parish
  • Infectious Disease Research Institute
  • Jubilant Biosys Ltd.
  • Eli Lilly

Research output: Contribution to journalArticlepeer-review

27 Citations (Scopus)

Abstract

Nitazoxanide has antiparasitic and antibiotic activities including activity against Mycobacterium tuberculosis. We prepared and evaluated a set of its analogues to determine the structure-activity relationship, and identified several amide- and urea-based analogues with low micromolar activity against M. tuberculosis in vitro. Pharmacokinetics in the rat suggested a path forward to obtain bioavailable compounds. The series had a good microbiological profile with bactericidal activity in vitro against replicating and nonreplicating M. tuberculosis. Analogues had limited activity against other Gram-positive bacteria but no activity against Gram-negative bacteria. Our studies identified the key liability in this series as cytotoxicity. Future work concentrating on identifying the target(s) could assist in removing activity against eukaryotic cells.

Original languageEnglish
Pages (from-to)5873-5890
Number of pages18
JournalACS Omega
Volume2
Issue number9
DOIs
Publication statusPublished - 30 Sept 2017
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'In Vitro Evaluation of Novel Nitazoxanide Derivatives against Mycobacterium tuberculosis'. Together they form a unique fingerprint.

Cite this